Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis

Summary

The investigator, the subject, and the sponsor's project team will remain blind throughout the study. Subjects will be randomly assigned to one of the three treatment groups at a ratio of 1:1:1 to be given the drug once a day for 4 weeks.

Timeline

Start

2023-03-18

Primary completion

2023-07-30

Completion

2023-12-30

Outcome

Met primary endpoint

release “ICP-332治疗中重度特应性皮炎（AD）II期临床研究达到主要终点。” innocarepharma.com ↗

Publications

• Xu J, Zhang L, Liang Y, Ji C, Xu A, Li Z, Li L, Lei T, Zhang C, Chen R, Tao X, Zhang R, Fang H, Zheng J, Yang W, Zhang G, Duan X, Ding Y, Yin W, Zhou W, Fan D, Du Y. Safety and Efficacy of ICP-332 for Moderate to Severe Atopic Dermatitis: A Phase 2 Randomized Clinical Trial. JAMA Dermatol. 2026 Mar 1;162(3):227-235. doi: 10.1001/jamadermatol.2025.5295.

Drugs

Indications